Avelumab and Merkel Cell Carcinoma: Examining the Causation Question

From Outbreak Communication to Occupational Risk Assessment

The legacy of general health and science communication has long emphasized broad public awareness, often focusing on infectious disease outbreaks such as the Ebola virus epidemic in West Africa, where situational mapping and case reporting were central to informing populations. This heritage established a framework for disseminating factual, accessible information about health risks without delving into mechanistic details. Transitioning from this broad context to a more specific occupational exposure concern requires a shift in focus—from population-level disease dynamics to individual-level pharmaceutical risk assessment. In the domain of mass production, where workers may encounter therapeutic agents during manufacturing, the question of causation between a drug and a disease becomes paramount. For instance, the relationship between Avelumab, a monoclonal antibody used in oncology, and Merkel Cell Carcinoma (MCC) warrants careful examination. While Avelumab is indicated for treating MCC, the concern here is not therapeutic efficacy but potential occupational exposure leading to disease development. This pivot moves the discussion from general health information to a targeted inquiry: whether exposure to Avelumab in production settings could be associated with an increased risk of MCC. The focus remains on exposure context, not disease mechanisms, preserving a neutral academic tone while bridging to occupational safety considerations.

Bridging to Medical Evidence: Avelumab Pharmacology and MCC

To address the question of causation, we must first understand the drug's intended use and mechanism. Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug's approval was based on the JAVELIN Merkel 200 trial, a two-part, single-arm, phase II study in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and incidence rates are increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often in older or immunocompromised individuals. Diagnosis is confirmed by histopathology and immunohistochemistry showing neuroendocrine markers.

Mechanistic Pathways: Therapeutic Action vs. Carcinogenesis

The mechanistic pathways linking avelumab to MCC are not indicative of causation but rather of therapeutic intent. Avelumab is designed to block PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells, including MCC cells. Immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcemia due to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids and allowed continuation of therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence suggests that avelumab induces de novo MCC. Instead, the drug is used to treat existing MCC, and its mechanism of action—immune checkpoint inhibition—is the same pathway that can lead to irAEs but not to the initiation of MCC.

Reported Adverse Effects and Risk Anchors

The primary risk consideration is not that avelumab causes MCC but that patients may experience progression or lack of response to therapy. Despite advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For avelumab-refractory patients, efficient and safe treatment options are lacking, though combined ipilimumab plus nivolumab has shown activity in such patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In a multicenter study, three out of five avelumab-refractory patients responded to combined ipilimumab plus nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab approved for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Warnings regarding avelumab and MCC are adequate in that the drug's prescribing information clearly states its indication for metastatic MCC and lists immune-related adverse events. However, no warning is needed for avelumab causing MCC because the drug is not a causative agent. The risk anchors for affected patients focus on the timeline between exposure and documented harm: harm from avelumab is typically related to irAEs, which can occur weeks to months after initiation, rather than to the development of a new malignancy. The timeline for MCC development is not applicable to avelumab exposure, as MCC is pre-existing or arises from other risk factors.

Causation-Related Considerations and Conclusion

For patients affected by MCC, causation considerations should focus on known risk factors such as ultraviolet light exposure, Merkel cell polyoma virus, and immunosuppression, rather than avelumab. The drug's role is therapeutic, and its use is associated with improved outcomes in metastatic MCC. The evidence does not support a causal link between avelumab and the development of MCC. Instead, avelumab is a treatment for MCC, and any adverse effects are related to immune activation, not oncogenesis. In summary, avelumab does not cause Merkel cell carcinoma. The drug is an approved treatment for metastatic MCC, and its mechanism of action involves immune checkpoint inhibition. Reported adverse events are immune-related and do not include induction of MCC. The evidence from clinical trials and case reports consistently positions avelumab as a therapeutic agent for MCC, not a causative factor. Risk considerations for patients should center on managing irAEs and addressing progression of disease, with no evidence supporting a causal relationship between avelumab exposure and MCC development.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel Cell Carcinoma?

No, Avelumab does not cause Merkel Cell Carcinoma. It is an FDA-approved treatment for metastatic MCC. The drug works by blocking PD-L1 to enhance the immune response against cancer cells. There is no evidence that Avelumab induces de novo MCC; rather, it is used to treat existing MCC.

What are the main risk factors for Merkel Cell Carcinoma?

The primary risk factors for MCC include chronic ultraviolet light exposure, infection with Merkel cell polyoma virus, and immunosuppression. Avelumab exposure is not a risk factor for developing MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.